Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anti-microRNA-21 therapy on top of ACE-inhibition delays renal failure in Alport syndrome mouse models

ABSTRACT: Anti-microRNA-21 therapy on top of ACE-inhibition delays renal failure in Alport syndrome mouse models

PROVIDER: PRJNA745946 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Anti-microRNA-21 therapy on top of ACE-inhibition delays renal failure in Alport syndrome mouse models

Project description:The goal of this study was to compare Next Generation mRNA (RNA-seq) data obtained from whole kidney tissue from WT and untreated, Lademirsen treated and Ramipril treated Col4a3-/- mice in the mixed 129/SvJ and B57BL/6J background

2022-02-04 | GSE179938 | GEO

RNA-Sequencing Quantitative Analysis of Mice Wild Type and Tg-ACE (ACE overexpression) Macrophages

Project description:In this study we compared transcriptome profiling (RNA-seq) in wild type vs. ACE overexpressiong Tg-ACE macrophages to identify differential gene expression/pathways.

2019-01-18 | GSE123952 | GEO

Anti-microRNA-21 prevents kidney failure in Alport syndrome by stimulating metabolic pathways

Project description:Anti-microRNA-21 prevents kidney failure in Alport syndrome by stimulating metabolic pathways

| PRJNA263791 | ENA

Alport (Col4a3-/-) Mouse Recapitulates Heart Failure with Preserved Ejection Fraction Pathologies Driven by Osteopontin-Mitochondria Axis

Project description:Alport (Col4a3-/-) Mouse Recapitulates Heart Failure with Preserved Ejection Fraction Pathologies Driven by Osteopontin-Mitochondria Axis

| PRJNA497812 | ENA

Uncovering Modifier Genes of X-linked Alport Syndrome Using a Novel Multi-parent Mouse Model

Project description:RNAseq of mouse kidney RNA from Col4a5 muntant mice crossed with diversity ourbred mice to find modifier genes of Alport disease.

2020-03-10 | GSE146660 | GEO

Transient ACE Inhibition Suppresses Future Fibrogenic Capacity and Heterogeneity of Cardiac Fibroblast Subpopulations

Project description:Transient angiotensin converting enzyme (ACE) inhibition in spontaneously hypertensive rats (SHR) protects against future injury-induced cardiac inflammation, fibrosis, and dysfunction. Here, we used single cell RNA sequencing (scRNA-Seq) to test the hypothesis that transient ACE inhibitor treatment would induce a persistent shift in hypertensive cardiac fibroblast subpopulations. Adult male SHRs (11 weeks old) were treated for 2 weeks with an ACE inhibitor, enalapril (30mg/kg/day, p.o.), or water (control) followed by a 2-week washout period (n=7/group). Cardiac fibroblasts were isolated from the left ventricle and subjected to scRNA-Seq. Nine clusters of fibroblasts (numbered 0-8) were identified with 98% of cells clustering into subsets 0-6. Transient treatment produced significant changes within and across clusters. Cluster 1 depicted the highly fibrogenic gene profile, with cluster 6 serving as a gateway to cluster 1. Transient ACE inhibition depleted the gateway and expanded cluster 0, which was the least fibrogenic profile. Moreover, within cluster 1 fibroblasts, ACE inhibition reduced expression of individual fibrosis genes (e.g. COL1A1, COL3A1, and FN1; all p<0.05). Clusters 2-5 reflected proliferative, moderately fibrogenic, translationally active, and lowly inflammatory subsets of fibroblasts, all of which exhibit attenuated fibrogenic gene expression after transient ACE inhibition. In conclusion, transient ACE inhibition shifts cardiac fibroblast subpopulations and degree of activation resulting in an overall reduced fibrogenic phenotype.

2020-10-01 | GSE155699 | GEO

Hippocampal gene expression profiling of a model of Alzheimer`s Disease upon treatment with the ACE inhibitor captopril

Project description:Extracellular senile plaques of amyloid beta (Abeta) are a pathological hallmark in brain of patients with Alzheimer`s Disease (AD). Abeta is generated by the amyloidogenic processing of the amyloid precursor protein (APP). Concomitant to Abeta load, AD brain is characterized by an increase in protein level and activity of the angiotensin-converting enzyme (ACE). ACE inhibitors are a widely used class of drugs with established benefits for patients with cardiovascular disease. However, the role of ACE and ACE inhibition in the development of Abeta plaques and the process of AD-related neurodegeneration is not clear since ACE was reported to degrade Abeta. To investigate the effect of ACE inhibition on AD-related pathomechanisms, we used Tg2576 mice with neuron-specific expression of APPSwe as AD model. From 12 months of age, substantial Abeta plaque load accumulates in the hippocampus of Tg2576 mice as a brain region, which is highly vulnerable to AD-related neurodegeneration. The effect of central ACE inhibition was studied by treatment of 12 month-old Tg2576 mice for six months with the brain penetrating ACE inhibitor captopril. At an age of 18 months, hippocampal gene expression profiling was performed of captopril-treated Tg2576 mice relative to untreated 18 month-old Tg2576 controls with high Abeta plaque load. As an additional control, we used 12 month-old Tg2576 mice with low Abeta plaque load. Whole genome microarray gene expression profiling revealed gene expression changes induced by the brain-penetrating ACE inhibitor captopril, which could reflect the neuro-regenerative potential of central ACE inhibition.

2013-05-14 | GSE46871 | GEO

Effects of endothelin A receptor blockade on renal interstitial disease in Alport mice

Project description:Total RNA was isolated from renal cortex from wild type and and alport mice given sitaxentan or vehicle from 2 to 7 weeks of age. RNA was analyzed by real time RT-PCR using the Qiagen Mouse Fibrosis PCR Array according to the manufacturer's instructions.

2016-04-30 | E-MTAB-3720 | biostudies-arrayexpress

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts.

Project description:Rationale: The molecular underpinnings of heart failure with reduced ejection fraction (HFrEF) involves a complex remodeling of the contractile, metabolic and electrical functions. Current pharmacotherapy for patients presenting HFrEF includes combination of angiotensin-converting enzyme inhibitors (ACEi) and β-adrenergic receptor blockers (β-AR blockers). Yet, a knowledge gap exists regarding the molecular changes accompanying such treatment. Objective: The present study takes an omics approach to study protein and phosphorylation signaling derangement in HFrEF and to define the global changes resulting from treatment with β-AR blocker (metoprolol) and ACE inhibitor (enalapril) in control- and HFrEF hearts.

2022-05-20 | PXD024525 | Pride

Osteopontin Deficiency Amerliorates Alport Kindey Pathology

Project description:Osteopontin Deficiency Amerliorates Alport Kindey Pathology

| PRJNA432010 | ENA